Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Fibrosis, Inflammatory Bowel Disease, and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SMAD7 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SMAD7 Recombinant Protein (Full-Length & MH2 Domain) High purity (>95% by SDS-PAGE), Endotoxin controlled (<1.0 EU/μg). Sequence Verified. |
View SMAD7 Products |
| Gene Delivery | SMAD7 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and reporter assay development. |
View SMAD7 Products |
| Benchmark Ab | Anti-SMAD7 Recombinant Antibody Sequence-verified positive control for ELISA, Western Blot, and IP validation. |
View SMAD7 Products |
| Validator | SMAD7 siRNA Set Target-specific knockdown verification to confirm assay specificity. |
View SMAD7 Products |
| Related Target A | TGFB1 (Transforming Growth Factor Beta 1) Upstream driver of the SMAD7 negative feedback loop; critical for pathway-wide screening. |
View TGFB1 Products |
| Related Target B | ALK5 (TGFBR1) Type I receptor that interacts directly with SMAD7; essential for protein-protein interaction (PPI) assays. |
View ALK5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular protein-protein interaction (PPI) mapping | MH2 domain-specific recombinant proteins available with strict endotoxin control and >95% purity. |
| High background noise in pathway reporter assays | Lentiviral vectors optimized for stable integration and uniform expression in target cell lines. |
| Lack of highly specific control antibodies | Sequence-verified clinical-grade recombinant antibodies ensuring batch-to-batch consistency. |
| Off-target assay interference | Target-specific validated siRNA sets included to confirm knockdown and verify assay specificity. |
Live SMAD7 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of SMAD7 represents a highly specialized niche within the TGF-beta/BMP signaling superfamily. Historically validated by antisense oligonucleotides (ASOs) in inflammatory bowel disease (IBD), the focus has expanded dramatically. The race for SMAD7 therapeutics is intensifying, with major players shifting focus from traditional mAbs to intracellular modalities such as small molecule PPI inhibitors, PROTAC-mediated degraders, and RNA-targeted therapeutics. As first-generation therapies reach the clinic, the next wave of R&D is targeting tissue-specific delivery and precise modulation of the SMAD7-ALK5-Smurf2 degradation complex to treat refractory fibrosis and cold tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antisense Oligonucleotides (ASO) | NIDDK, Academic Consortia | Inflammatory Bowel Disease (IBD), Crohn's Disease | Knockdown Validation (Need validated siRNA and high-spec qPCR controls) |
| Small Molecule PPI Inhibitors | Biotech Startups, Oncology Pioneers | Solid Tumors, Fibrotic Diseases | Binding Affinity/Kinetics (Need high-purity recombinant SMAD7 MH2 domain) |
| Gene Therapy / Overexpression | Ophthalmic & Pulmonary Biotechs | Corneal Scarring, Pulmonary Fibrosis | Stable Cell Line Construction (Need high-titer SMAD7 Lentivirus) |